Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BioNTech SE
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/10/2023
144/A
Form 144/A - Report of proposed sale of securities: [Amend]
09/29/2023
144
Form 144 - Report of proposed sale of securities:
09/29/2023
144
Form 144 - Report of proposed sale of securities:
08/14/2023
144/A
Form 144/A - Report of proposed sale of securities: [Amend]
08/14/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
",
"
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
"
08/07/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Quarterly Report for the Three and Six Months Ended June 30, 2023
",
"
Quarterly Report for the Three and Six Months Ended June 30, 2023
"
08/07/2023
6-K
Quarterly results
Docs:
"
6-K
",
"
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
",
"
Second Quarter 2023: Corporate Update and Financial Results
"
07/31/2023
6-K
Quarterly results
06/29/2023
144
Form 144 - Report of proposed sale of securities:
06/29/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 program in Metastatic NSCLC
",
"
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 program in Metastatic NSCLC
"
06/28/2023
144
Form 144 - Report of proposed sale of securities:
06/02/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
",
"
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
"
06/02/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016
",
"
Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016
"
05/26/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
",
"
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
"
05/25/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Annual General Meeting 2023 Voting Results
",
"
Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023
",
"
Annual General Meeting 2023 Presentation
",
"
Annual General Meeting 2023 Voting Results
"
05/08/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Quarterly Report for the Three Months Ended March 31, 2023
",
"
Quarterly Report for the Three Months Ended March 31, 2023
"
05/08/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Quarterly Report for the Three Months Ended March 31, 2023
",
"
Quarterly Report for the Three Months Ended March 31, 2023
"
05/08/2023
6-K
Quarterly results
04/13/2023
6-K
Quarterly results
04/03/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
",
"
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
"
03/28/2023
6-K
Quarterly results
03/27/2023
20-F
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/27/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
6-K
",
"
BioNTech Announces Full Year 2022 Financial Results and Corporate Update
",
"
Fourth Quarter and Full Year 2022: Corporate Update and Financial Results
"
03/20/2023
6-K
Quarterly results
03/01/2023
6-K
Quarterly results
02/24/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster
",
"
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster
"
02/21/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023
SC 13G/A
ATHOS KG reports a 43.5% stake in BIONTECH SE
02/13/2023
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
02/13/2023
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
01/10/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech Presents at JP Morgan Healthcare Conference 2023
",
"
BioNTech Presents at JP Morgan Healthcare Conference 2023
"
01/10/2023
6-K
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs:
"
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
",
"
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
"
12/22/2022
6-K
Quarterly results
12/09/2022
6-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy